Search

1023 Result(s)
Sort by

Their dogs are their world

Their dogs are their world

Corporate social responsibility in Brazil: Volunteer work and animal healthcare donations for homeless people and their pets.
S&P Animal Health Partnering Oct 2023

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
GPP Interview with Professor Barker

GPP Interview with Professor Barker

An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Spotlight on GPP

Spotlight on GPP

Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
More Potential

More Potential

Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
SPEVIGO®

SPEVIGO®

SPEVIGO® (spesolimab) is a novel, humanized, selective antibody for the treatment of generalized pustular psoriasis (GPP) flares.
Spiriva®

Spiriva®

Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), maintenance treatment of associated dyspnoea and for prevention of exacerbations.
Spiriva® Respimat®

Spiriva® Respimat®

An add-on maintenance treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids.
Spiolto® Respimat®

Spiolto® Respimat®

Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Striverdi® Respimat®

Striverdi® Respimat®

Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Combivent® Respimat®

Combivent® Respimat®

A combination of a short-acting anticholinergic and beta-adrenergic for the management of reversible bronchospasms associated with obstructive airway diseases in patients requiring more than one bronchodilator.
Aggrenox®

Aggrenox®

Prevention of stroke following an initial first stroke, or transient ischaemic attacks (TIA).
Metalyse®

Metalyse®

Fibrinolytic treatment of acute myocardial infarction. Fibrinolytic treatment of acute ischaemic stroke.
Trajenta®

Trajenta®

Treatment of type 2 diabetes mellitus to improve glycaemic control in adults, used in monotherapy (if metformin is not tolerated or contraindicated) or in combination therapy.
Twynsta®

Twynsta®

Treatment of hypertension alone or with other antihypertensive agents. As initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals (USA). Add-on therapy in adult patients with not adequately co
Sifrol®

Sifrol®

Symptomatic treatment of idiopathic Parkinson’s disease. It may be used as monotherapy or in combination with levodopa. Symptomatic treatment of idiopathic moderate to severe restless legs syndrome.
Actilyse®

Actilyse®

Fibrinolytic treatment of acute ischaemic stroke, acute myocardial infarction, acute massive pulmonary embolism. Fibrinolytic treatment of occluded catheters.
MicardisPlus®

MicardisPlus®

US: Treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Not indicated for